Wall Street analysts forecast that Zimmer Biomet (ZBH) will report quarterly earnings of $1.98 per share in its upcoming release, pointing to a year-over-year increase of 8.8%. It is anticipated that revenues will amount to $1.94 billion, exhibiting an increase of 3.7% compared to the year-ago quarter. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. is set to report its second-quarter 2024 results on August 7, with expectations of revenue growth and improved earnings per share compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for second-quarter 2024 revenues is $1.94 billion, reflecting a 3.7% increase from the prior year [2]. - The expected earnings per share for the second quarter is $1.98, indicating an 8.8% improvement from the year-ago adjusted earnings [2]. Estimate Revision Trend Ahead of Earnings - The earnings estimate for Zimmer Biomet has remained unchanged at $1.98 per share over the past 60 days, indicating stability in expectations leading up to the earnings announcement [3]. Factors at Play - The company faces supply challenges due to geopolitical issues and healthcare labor shortages, which have impacted margins. However, it anticipates these challenges to ease, supported by a strong product pipeline and effective growth strategies [4]. - Procedure volume improvement in the legacy business and strong performance in the Knees and Hip segments are expected to drive revenue growth [5]. Business Segment Performance - **Hips Business**: Anticipated recovery in procedure volume due to strategic product launches, including the FDA-approved triple taper hip stem Z1 and advancements in navigation technology. Projected growth of 2.5% year-over-year in the second quarter [6][7]. - **Knees Business**: Expected strong recovery in elective procedures and market penetration of the cementless knee system, with projected revenue growth of 2.8% year-over-year [8][10]. - **S.E.T. Business**: Anticipated strong performance in craniomaxillofacial and sports medicine areas, with projected year-over-year revenue growth of 8%. However, there may be pressures from reimbursement challenges and supply issues [11][12]. Earnings ESP and Zacks Rank - Zimmer Biomet has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold), indicating a lower likelihood of beating earnings estimates compared to other stocks with higher ranks [13].

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 204- 4368 and using conference ID 5103691. International callers should dial +1 (323) 994-2093 and use conference ID 5103691. SOURCE Zimmer Biomet Holdings, Inc. Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital an ...

PhonlamaiPhoto Zimmer Biomet's (NYSE:ZBH) share price has been under considerable pressure over the past 3 months, potentially due to a combination of soft growth, poor cash flows and higher interest rates. Some of these issues are expected to begin correcting later in the year though. I previously suggested that concerns over the impact of weight loss drugs was misplaced, with reduced obesity rates likely to provide a demand boost in the near term. The rise of robotic surgeries and Zimmer's evolving produc ...

WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (Nasdaq: EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are plea ...

Zimmer Biomet (ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions, which, in turn, should help the advancement of value-based orthopedic care and health equity. More on the Partnership About RevelAi Health It offers a unique patient care management system, managing text messages and clinician-guided voice agents to enhance patient engagement. Industry Prospects Simultaneously, the global value-based healt ...

Zimmer Biomet Holdings, Inc. (ZBH) entered into a limited distribution agreement with Think Surgical Inc. to expand its knee surgery product business. Per the terms of the agreement, Zimmer Biomet will offer Think Surgical's wireless, handheld TMINI - Miniature Robotic System for total knee arthroplasty. More in the News As ZBH's core focus remains on advancing technologies for total knee replacement, this collaboration should help strengthen Zimmer Biomet's position in this market. About TMINI Image Source ...

RevelAi Health is a software as a service (SAAS) health technology company that specializes in cutting-edge generative AI population health solutions. RevelAi Health's clinician-validated large language model helps healthcare providers transition seamlessly to value-based care, meeting essential CMS (Centers for Medicare & Medicaid Services) requirements, including Patient Reported Outcome measures and Social Drivers of Health (SDOH) Screening. For more information about this partnership and the technologie ...

--TMINI System Complements Company's Flagship ROSA® Robotics Portfolio Featuring Applications for Knee, Hip and Shoulder Arthroplasty-- "We are proud to be the first medtech company to offer two complementary robotic systems for surgeons looking to incorporate robotic assistance while performing a knee replacement," said Dr. Nitin Goyal, Chief Science, Technology and Innovation Officer at Zimmer Biomet. "TMINI addresses surgeon demand for an ergonomic, wireless, handheld robotic system and now, in addition ...

Despite a sizable day rate headwind and difficult year-over-year comps in the first quarter, U.S. sales rose 3.7% year over year. Since the beginning of 2024, procedure volume has been very strong in both Knees and Hips, banking on an improved market scenario. International sales grew 5.4% year over year at a constant exchange rate. All regions benefited primarily from continued growth in the Knee category as well as strong commercial execution and new product uptake. Zimmer Biomet (ZBH) is witnessing volum ...